S-1/A: Functional Brands Files S-1/A for Nasdaq Direct Listing

Functional Brands Inc. filed an S-1/A registration statement for a direct listing on the Nasdaq Capital Market, aiming to register 17.88 million shares for resale and raise $8 million through a private placement to address existing liabilities and fund growth.

Summary

• Functional Brands Inc. is pursuing a direct listing on the Nasdaq Capital Market under the symbol MEHA, registering 17,883,693 shares of common stock for resale by existing stockholders.
• The company has secured an $8,000,000 private placement transaction through the sale of Series A and Series B Convertible Preferred Stock, with expected net proceeds of approximately $6,464,106.
• A portion of the private placement proceeds will be used to cure an existing default of $2,227,366 related to the Kirkman acquisition, with the remaining funds allocated for general working capital and growth initiatives.
• For the fiscal year ended December 31, 2024, net revenue was $6,566,455, a 4% decrease from $6,820,499 in 2023, while net loss improved to $(559,356) from $(1,241,094) in 2023.
• For the six months ended June 30, 2025, net revenue decreased by 2% to $3,422,789 compared to $3,490,446 in the prior year period, and the company reported a net loss of $(352,838) compared to a net income of $6,475 in the same period of 2024.
• The independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
• The company operates in the nutraceutical supplement industry through its Kirkman brand and in the hemp industry with its HempTown Naturals and Golf Mellow brands.
• The Kirkman brand, established in 1949, offers over 150 products and operates a FDA registered, cGMP certified facility, known for rigorous testing standards that exceed FDA requirements.
• In April 2024, the company launched P2i by Kirkman, a certified prenatal vitamin aligning with FIGO's low-toxicity standards, which is highlighted as the only one of its kind in the market.
• The company is negotiating the termination of its exclusive license agreement with Trailer Park Boys for hemp-derived Delta 9 products, which currently represent approximately 0.6% of total revenue, effective December 31, 2025.
• Functional Brands Inc. ceased to be a controlled company as of August 5, 2025, and August 11, 2025, following the distribution of shares by its former parent, Hemptown Organics Corp.

Sentiment

Score: 3

Explanation: The company is undertaking a direct listing and has secured significant private placement funding, which are positive steps. However, the financial performance shows worsening losses in the most recent interim period, continued negative cash flow, and an auditor's going concern doubt. The company also faces substantial debt obligations and regulatory uncertainties in the hemp industry. The direct listing process itself carries high volatility risks due to the absence of traditional underwriting and price discovery mechanisms. These factors collectively indicate a high-risk investment with significant downside potential.

Positives

• Successfully launched P2i by Kirkman prenatal vitamin in April 2024, which is certified as the only one aligning with FIGO's low-toxicity standards, indicating a strong competitive advantage in a growing market segment.
• The Kirkman brand boasts over 70 years of operation with a loyal consumer base and maintains high purity and quality standards, including testing for 90 metals and toxins in raw materials, exceeding FDA requirements for dietary supplements.
• Achieved a significant 55% reduction in net loss from $(1,241,094) in 2023 to $(559,356) in 2024, demonstrating improved cost controls and vendor terms.
• Secured $8,000,000 in gross proceeds from a private placement of convertible preferred stock, providing crucial capital to address existing liabilities and fund future growth initiatives.
• The company has a clear growth strategy focused on strengthening existing brands, launching new niche products, modernizing manufacturing capabilities, and increasing sales and distribution through enhanced marketing and business development.
• Functional Brands Inc. is no longer a controlled company, which may lead to improved corporate governance and broader investor appeal.

Negatives

• The independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows from operations.
• Net loss significantly worsened for the six months ended June 30, 2025, reaching $(352,838) compared to a net income of $6,475 for the same period in 2024.
• Revenue decreased by 2% for the six months ended June 30, 2025, and by 4% for the full year 2024, primarily due to lower demand from contract manufacturing customers.
• The company has a significant accumulated deficit of $(8,013,768) as of June 30, 2025, and negative working capital of $(1,819,384).
• An existing default of $2,227,366 on the Kirkman acquisition payment is due by August 30, 2025, with a confession of judgment allowing for potential foreclosure on assets if not cured.
• High customer concentration, with two customers accounting for 55% of sales for the six months ended June 30, 2025, and one customer representing 78% of accounts receivable.
• The exclusive license agreement with Trailer Park Boys, representing only 0.6% of total revenue, is being negotiated for termination, indicating a lack of significant contribution from this segment.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
• The company may be unable to effectively manage future growth, leading to capacity constraints and pressure on internal systems.
• Additional financing will be required in the future, which may not be available when needed or may be costly and dilutive to existing shareholders.
• A limited operating history makes it difficult to evaluate the proposed business and prospects, with no assurance of achieving profitability.
• The company may incur significant debt in the future and faces risks of default on existing debt, including the Kirkman acquisition payment, which could lead to foreclosure on assets.
• The nutraceutical and hemp industries are highly competitive, with larger, well-financed competitors potentially affecting distribution relationships and market expansion.
• The company's brand and image are critical, and negative public relations or product quality issues could adversely affect results of operations.
• The industry is characterized by rapid changes in consumer preferences, requiring continuous development of new products to maintain long-term success.
• Uncertain and evolving federal, state, and local regulations concerning hemp, CBD, CBG, and other non-tobacco consumable products pose significant risks, including potential illegality or increased compliance costs.
• The psychedelic therapy industry and market are relatively new and may not continue to exist or grow as anticipated, impacting related product lines.
• Reliance on distributors, retailers, and brokers could affect efficient and profitable product distribution and market expansion.
• Loss of key distributors or retail accounts would harm the business due to significant time and expense incurred in attracting and maintaining them.
• Disruptions within the supply chain, contract manufacturing, or distribution channels due to various factors (e.g., natural disasters, pandemics, labor strikes) could adversely affect business.
• The company relies on two major customers for a substantial portion of its revenues, and the loss of either could significantly harm the business.
• Wholesale price volatility for hemp and other product ingredients may adversely affect operating income and profitability.
• The company may sustain losses that cannot be recovered through insurance or other preventative measures, as current liability coverage may be inadequate.
• Product liability claims and product quality issues, including recalls, could lead to significant liabilities and damage reputation.
• Difficulty in predicting the timing and amount of sales, particularly for new products and markets, results in uncertain sales forecasts.
• Inability to adequately manage inventory levels could adversely affect operating results due to higher storage costs or spoilage.
• Increases in costs or shortages of raw materials could harm business and financial results.
• Increases in energy costs and increased regulations may have an adverse impact on gross margin.
• Inability to attract and retain key personnel, including the Chief Executive Officer and Chief Financial Officer, could impair future operations.
• Failure to protect trademarks and trade secrets could hinder successful product marketing and effective competition.
• Disruptions to information technology systems due to cyber-attacks or failure to upgrade could materially impair operations.
• Noncompliance with numerous federal, state, and local regulations is costly and could result in fines or production stoppages.
• Significant additional labeling or warning requirements may inhibit sales of affected products.
• The industry may become subject to expanded regulation and increased enforcement by the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC).
• Results of operations may fluctuate from quarter to quarter due to seasonality and other factors.
• Global economic, political, and social conditions, including geopolitical instability and potential tariffs, may adversely impact business and results of operations.
• There is no assurance that the company will satisfy Nasdaq listing requirements or obtain/maintain a listing of its common stock.
• The direct listing process differs significantly from an initial public offering, potentially leading to greater price and volume volatility, and an uncertain trading market.
• Future sales of common stock by Registered Stockholders and other existing stockholders could cause the share price to decline due to potential oversupply.
• Future issuances of preferred stock or additional common stock could dilute existing shareholders and adversely affect the stock price.
• No current plans to pay cash dividends mean shareholders may not receive a return on investment unless they sell their shares.
• If securities industry analysts do not publish research reports or publish unfavorable reports, the market price and trading volume could be negatively affected.
• Future issuances of debt securities would rank senior to common stock upon bankruptcy or liquidation, and preferred stock could rank senior for dividends and liquidating distributions.
• The company is authorized to issue blank check preferred stock without stockholder approval, which could adversely impact common stock rights.
• If the common stock becomes subject to penny stock rules, it would become more difficult to trade shares.
• As an emerging growth company and smaller reporting company, reduced disclosure requirements may make the common stock less attractive to investors.

Future Outlook

The company aims to become a leader in the nutraceutical space by manufacturing high-quality products, building a diverse portfolio including mushroom-based and prenatal supplements, and modernizing its manufacturing capabilities. It plans to significantly enhance output, invest heavily in sales and marketing, and pursue strategic partnerships or acquisitions. Proceeds from the private placement are intended to cure existing debt and fund these growth initiatives.

Management Comments

• Eric Gripentrog (CEO): "His expertise in leading a business, managing the P&L and identifying margin enhancing opportunities for both business-to-business and direct-to-consumer clientele is critically important for the current role."
• Tariq Rahim (CFO): "He has tremendous experience in leveraging his financial skills to lead companies and clients through the full gamut of accounting and finance challenges – strategic planning, financial reporting, financial planning & analysis, budgeting & forecasting, to mention just a few."

Industry Context

The company operates within the growing global nutraceutical and dietary supplement markets, valued at $405.15 billion and $53.6 billion respectively in 2023, with projected CAGRs of 6.3% and 5.7% through 2030, driven by increasing health awareness. The global CBD consumer health market, valued at $19.5 billion in 2023, is also experiencing rapid growth (18.1% CAGR), influenced by legalization reforms and health benefits awareness. The U.S. market is a significant contributor to these trends. The FDA's evolving stance on CBD, awaiting Congressional direction, creates regulatory uncertainty, though the company focuses on compliance by avoiding disease claims and youth appeal.

Comparison to Industry Standards

• The Kirkman brand's 75+ year history and rigorous material testing, including screening for approximately 90 metals and toxins in raw materials, exceed standard FDA requirements for dietary supplements, which do not mandate such extensive testing.
• The P2i by Kirkman prenatal vitamin is highlighted as the 'only certified prenatal vitamin in the market that aligns to the FIGO position statement,' which recommends independent assessment for contaminants like 24 heavy metals and 120 toxic chemicals, setting a high bar for product purity.
• The company's practice of testing every batch of products for heavy metals (below Prop 65 limits) and microbial contamination is a more stringent quality control measure compared to the FDA's allowance for statistical sampling for finished dietary supplements.
• The company's hemp-derived products comply with the US 2018 Farm Bill, which legalized hemp with less than 0.3% THC, aligning with federal standards, unlike some products that may operate in a more ambiguous regulatory space.

Management Changes

Corporate Governance

Legal Proceedings

• True Health Medical Center, S.C. vs. Kirkman Group, Inc., James Hall, David Humphries, HTO Nevada, Inc., and HTO Holdings, Inc.: A lawsuit pending in the Circuit Court for the Eighteenth Judicial Circuit, DuPage County, Illinois.
• True Health claims Kirkman underpaid royalties prior to selling assets to HTO Parties and contends that HTO Parties should be bound by the royalty agreement.
• There is no certain amount of damages claimed against the HTO Parties at this time.
• The outcome of the proceeding is unpredictable, and additional discovery or motion practice is expected, which will likely delay the prospective trial date.

Related Party Transactions

• Loan agreement with Eric Gripentrog (CEO) for $130,000 on March 11, 2024, at 20% annual interest, due March 11, 2031.
• Loan agreement with Eric Gripentrog (CEO) for $225,000 on March 10, 2025, at 18% annual interest, due March 7, 2029.
• A short-term debt facility of $247,634 entered in December 2023 with an officer and director of the parent company (Hemptown Organics Corp.) was non-interest-bearing and reclassified to a non-related party loan in January 2025 after the officer resigned.
• The licensing agreement dated December 10, 2020, with Hemptown Organics Corp. (former parent) for the Hemptown Naturals brand will transfer full ownership to Functional Brands upon the effective date of the registration statement and listing.
• The acquisition of HTO Nevada Inc. dba Kirkman on May 19, 2023, involved a share exchange agreement with Hemptown Organics Corp. and HTO Holdings Inc. (related parties), resulting in the issuance of 4,362,378 common shares.
• An exclusive license agreement with Trailer Park Boys (TBP) for hemp-derived Delta 9 products involved payments of $575,000 to date and the issuance of 14,440 shares. The company is negotiating termination of this agreement by December 31, 2025, with up to $150,000 in remaining accrued royalties due by March 31, 2026.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances and no planned cash dividends, meaning returns depend solely on stock price appreciation. The direct listing process itself carries high volatility risks, and existing shareholders may sell, potentially causing price declines.
• Employees are critical to success, and the company's ability to attract and retain highly qualified personnel, including key executives like the CEO and CFO, is vital; loss of these individuals could impair operations.
• Customers may be impacted by product quality issues, recalls, or changes in consumer preferences. The high concentration of revenue from two major customers (iHerb and OceanSide Health) poses a significant business risk if these relationships deteriorate.
• Suppliers and creditors face risks related to potential disruptions in the supply chain, increases in raw material costs, and the company's existing debt defaults and forbearance agreements, which could affect timely payments.
• Regulatory bodies will continue to oversee the company's operations in the nutraceutical and hemp industries, with evolving regulations potentially imposing additional compliance burdens and costs.

Next Steps

• Complete the direct listing on the Nasdaq Capital Market under the symbol MEHA.
• Utilize private placement proceeds to cure the existing default on the Kirkman acquisition payment by August 30, 2025.
• Allocate approximately $2.3 million from private placement for sales, marketing, and general working capital.
• Modernize manufacturing capabilities by reorganizing space and introducing new machinery and equipment.
• Invest heavily into sales and marketing activities as well as business development to increase sales and distribution.
• Identify key companies with synergistic strengths for partnerships or acquisitions.
• Negotiate the termination of the Trailer Park Boys license agreement effective December 31, 2025, with remaining accrued royalties to be paid by March 31, 2026.
• Potentially enter into an Equity Line of Credit facility for $15-$25 million with the Purchaser having the highest Subscription Amount at Closing.
• Continue to monitor and comply with evolving federal, state, and local regulations concerning hemp and nutraceutical products.
• Address the ongoing legal proceeding with True Health Medical Center, S.C., which is expected to involve additional discovery or motion practice.

Key Dates

Recommendation

The filing reveals significant financial distress, including recurring losses, negative cash flow, and an auditor's going concern doubt. While the direct listing and private placement aim to raise capital, the company's current financial state is precarious, marked by substantial accumulated deficit and negative working capital. The reliance on a few key customers and the ongoing legal and regulatory uncertainties in the hemp industry add further risk. The direct listing process itself carries high volatility risks due to the absence of traditional underwriting and price discovery mechanisms. These factors collectively indicate a high-risk investment with significant downside potential.

Keywords

Nutraceuticals, Supplements, Hemp, CBD, CBG, Direct Listing, Nasdaq, Functional Brands, Kirkman, P2i, Health Supplements, Dietary Supplements, SEC Filing, S-1/A, Corporate Governance, Risk Management